Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid...
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
News Details - Moderna
Mar 26, 2024 · In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
News Details - Moderna
Mar 27, 2024 · Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
News Details - Moderna
Jun 10, 2024 · CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.
Moderna says mRNA flu shot generates better immune response …
Sep 13, 2023 · Moderna is racing Pfizer to bring mRNA technology to seasonal flu vaccines in a bid to improve how well they can target circulating strains. The companies also have plans to combine Covid-19...
News Details - Moderna
Sep 6, 2023 · Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants
News Details - Moderna
Oct 24, 2023 · mRNA-1083 is Moderna's first respiratory combination vaccine candidate to enter a Phase 3 trial. Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines.
Combined COVID–flu vaccines are coming: Moderna jab clears
Jun 28, 2024 · Moderna is now planning to seek approval from the US Food and Drug Administration (FDA) to bring the vaccine to market. Combination vaccines can have big public-health benefits, but they are...
Moderna says Covid-flu combination vaccine shows positive …
Jun 10, 2024 · Vaccine maker Moderna announced positive late-stage trial results for its Covid-flu combination vaccine. There could be a combined Covid-19 and flu shot in our future, although it won’t be ready...